Skip to content

Apollomics vs Glycyx

Apollomics logo

Apollomics

We are a biopharmaceutical company committed to the discovery and development of mono- and combination cancer therapies

26 employees · est. 2015 · Foster City, United States

VS
Glycyx logo

Glycyx

Restoring immune response in cancer: reversing Opioid-Induced Immunodeficiency to enhance immunotherapy efficacy

3 employees · est. 2020 · San Francisco, United States

Apollomics is the older company (2015 vs 2020); Apollomics is the larger of the two.

Side-by-Side Comparison

Apollomics Glycyx
Founded
2015 older 2020
Headquarters
Foster City, United States San Francisco, United States
Employees
26 larger 3
Industry
Biotechnology, Health Care, Pharmaceutical Biopharma, Biotechnology, Pharmaceutical
Funding Stage
Post-IPO Equity Series A
Total Funding
$262.60M $7.10M
Funding Rounds
5 3
Services
Not tracked yet Development of therapies that restore immune function, Combination treatments with immune checkpoint inhibitors, Enhanced T-cell infiltration into tumors, Inhibition of opioid-induced immune suppression
Target Customers
Not tracked yet Cancer patients, Healthcare providers, Oncologists, Pharmaceutical companies
Taxonomy
Biopharmaceutical CompanyOncology TherapiesCombination TherapiesCancer TreatmentDrug DevelopmentImmune System +8 Cancer TreatmentImmunotherapyOpioid-Induced ImmunodeficiencyImmune Checkpoint InhibitorsPeripherally Restricted Opioid AntagonistPhase 2 Clinical Trials +8
Website
apollomicsinc.com glycyx.com
Apollomics logo

About Apollomics

Apollomics is a biopharmaceutical company with a clear mission to discover and develop mono- and combination cancer therapies. Established in 2016, Apollomics has made strategic moves to operate in both the U.S. and China, aiming to harness synergies by collaborating with biotechnology companies in...

Glycyx logo

About Glycyx

Glycyx, a highly innovative biotech firm founded in 2020 and headquartered in the United States, is tackling a critical yet often overlooked challenge in cancer treatment—opioid-induced immunodeficiency that diminishes the efficacy of immunotherapy. Known as Opioid-Induced Immunotherapy Failure (OII...

Also comparing in this category

Comparing more than these two?

Get Apollomics, Glycyx and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does Apollomics compare?

A PDF of Apollomics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

Apollomics was founded in 2015, based in Foster City, United States, with 26 employees. Apollomics is a biopharmaceutical company with a clear mission to discover and develop mono- and combination cancer therapies. Established in 2016, Apollomics has made strategic moves to operate in bo. Glycyx was founded in 2020, based in San Francisco, United States, with 3 employees. Glycyx, a highly innovative biotech firm founded in 2020 and headquartered in the United States, is tackling a critical yet often overlooked challenge in cancer treatment—opioid-induced immunodeficien.
Apollomics has raised $262.60M and Glycyx $7.10M. Latest stage: Apollomics Post-IPO Equity, Glycyx Series A.
Both work in Biotechnology and Pharmaceutical and list cancer treatment and immunotherapy among their focus areas.

Compare Apollomics with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Apollomics on 12 Sep 2024, and Glycyx on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout